# LEAP-001 (NCT03884101)

> Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)

No report yet. It can be ordered.

- Drugs tested: lenvatinib plus pembrolizumab
- Indication: first-line advanced or recurrent endometrial cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03884101
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Endometrial Neoplasms
- Interventions: Lenvatinib; Pembrolizumab; Paclitaxel; Carboplatin
- Enrollment: 842
- Primary outcome: Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants
- Primary outcome: PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants
- Primary outcome: Overall Survival (OS) in pMMR Participants
- Primary outcome: OS in All Randomized Participants

## Some of the questions raised in the 40 most recent indexed sources

_Automated from the 40 newest of 66 indexed sources (Apr 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether patients with prior (neo)adjuvant platinum gain more from lenvatinib-pembrolizumab than from carboplatin-paclitaxel
- Whether carboplatin-paclitaxel alone remains a relevant control arm now that chemotherapy plus immunotherapy is standard
- Whether the dMMR subgroup supports dropping chemotherapy from first-line immunotherapy-based treatment

## Indexed commentary on LEAP-001 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 28 podcast episodes
- 27 YouTube videos
- 11 posts on X

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=leap-001-nct03884101

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03884101", "email": "<work email>"}; the inbox owner confirms by the emailed link.
